An overview of pathophysiology and treatment of insulin resistance

Indian Journal of Physiology and Pharmacology

Volumn 45, Issue 1, 2001, Pages 22-36

  Umrani, D N ^a   Goyal, R K ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

Insulin resistance Hyperinsulinemia; Non insulin dependent diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CIGLITAZONE; DICHLOROACETIC ACID; ENGLITAZONE; GLUCOSE; GLUCOSE TRANSPORTER; GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; LIPID; PHOSPHOTRANSFERASE; PIOGLITAZONE; TROGLITAZONE; VANADIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MONOSACCHARIDE TRANSPORT PROTEINS; PHOSPHOTRANSFERASES; SIGNAL TRANSDUCTION;

EID: 0035173329     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Serum insulin in essential hypertension and peripheral vascular disease
2. Epidemiology of hypertension associated with diabetes mellitus
3. Obesity and hypertension mechanisms and implications for management
4. Classification of diabetes mellitus and other categories of glucose intolerance
5. Hyperinsulinemia and insulin insensitivity studies in subjects with insulinoma
6. Plasma triglycerides in human diabetes
7. Relationship of multiple variables to blood pressure finding from four Chicago epidemiologic studies
8. Role insulin in endogenous hypertriglyceridemia
9. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemic men
10. Relationship between obesity maximal; insulin stimulated glucose uptake in vivo and in vitro Pima Indians
11. Effect of insulin peripheral and splanchnic glucose metabolism in non insulin dependent (Type 2) diabetes mellitus
12. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus: Evidence for multiple site for insulin resistance
13. Insulin Receptor post receptor defects contribute to the insulin resistance in non-insulin dependent diabetes mellitus
14. Obesity, metabolism and the sympathetic nervous system
15. Obesity and insulin resistance in man: A dose response study
16. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease
17. Role of insulin resistance in human disease
18. The like between insulin resistance and hypertension effect of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity
19. Patients with insulinoma show insulin resistance in the absence of arterial hypertension
20. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man
21. Plasma triglyceride as a risk factor for coronary heart disease, the epidemiologic evidence and beyond
22. The triglyceride issue: A view from Framingham Study
23. Endothelial dysfunction: Cause of the insulin resistance syndrome
24. Endothelium derive contracting factors
25. Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular disease in diabetes
26. Insulin receptors and action on vascular cells
27. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: A potential role for serine phophorylation in insulin/angiotensin cross-talk
28. Differential signaling by Insulin receptor substrate 1 (IRS-I)and IRS-II in IRS-I deficient cells
29. Identification of a novel inositol signaling pathway with significant therapeutic relevance to insulin resistance: An insulin signaling model using both tyrosine kinase and G-proteins
30. Action of insulin modulated by pertussis toxin in rat adipocytes
31. The action of islet activation Protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclicAMP phosphodiesterases in hepatocytes
32. A pertussis toxin sensitive G protein mediates some aspects of insulin actions in BC3H1 routine myocytes
33. Insulin oral hypoglycemic agents, and the pharmacology of endocrine pancreas
34. Insulin stimulation of mitogen activated protein Kinasem, p90rsk, and p70 S6 Kinase in skeletal muscle of normal and insulin resistant mice
35. Insulin action and insulin signaling network
36. From receptor to transporter: Insulin signaling to glucose transport
37. Moving GLUT4. The Biogenesis and trafficking of GLUT4 storage vesicles
38. Defect in skeletal Muscle, phosphatidyinositon-3-Kinase in obese insulin - Resistant mice
39. Molecular mechanisms of insulin action in normal and insulin resistant state
40. Cross-talk between the platelet Growth Factor and the insulin signaling pathways in 3-T-3 L1 adipocytes
41. Effects and binding of insulin like grown factor I in the isolated solcus muscle of lean and obese mice: A comparison with insulin Endocrinology
42. Effect of IGF-3 on phophatidylinostitol 3-Kinase in soleus muscle of lean and insulin resistant obese mice
43. Perspectives of the hyperinsulinemia/insulin resistance syndrome
44. Molecular biology of mammalian glucose transporters
45. A mutation in the glut 2 glucose transporter gene of a diabetic patient abolishes transport activity
46. Molecular physiology and genetics of NIDDM
47. Peroxisome proliferator activated receptor alpha in metabolic disease, inflammation atherosclerosis and aging
48. Do antihypertensive drugs precipitate diabetes?
49. Glucose intolerance in hypertensive patients-treated with diureics: A fourteen year follow up
50. Glucose tolerance during anthipertensive therapy in patients with diabetes mellitus
51. A comparison of effects of hydrochlorothiaizide and captopril on glucoe and lipid metabolism in patients with hypertension
52. Metabolic effects of diltiazem and atenolol: Results from a randomized, double blind study with parallel groups
53. Prevalence of hypertension and comparative evaluation of four antihypertensive monotherapies in Indian NIDDM hypertensive patients
54. Spirapril attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats
55. Effect of nifedipine and enalapril on insulin induced glucose disposal in spontaneously hypertensive and diabetic rats
56. Effect of chronic treatment with amlodipine in streptozotocin diabetic and spontaneously hypertensive rats
57. Effects of chronic treatment with amlodipine in non-insulin dependent diabetic rats
58. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone
59. Reduction in insulin resistance in obese and /or diabetic animals by 5-[4-(1-methyicyclohexyimrthoxy)-benzyI] thiazolidine-2, 4-dione (ADD-3878, U-63287, ciglitazone) a new antidiabetic agent
60. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids
61. Hypoglycemic agents which do not release insulin
62. Antihyperglycemic thiazolidinediones
63. PPAR-γ adipogenic regulator and thiazolidinedione receptor
64. Dichloroacetate
65. Insulin mimetic effects of vanadate possible implications for future treatment of diabetes
66. Effect of vanadate on blood glucose and depressed cardiac performance of diabetic rats
67. The glucose fatty acid cycle
68. Rationale and application of fatty acid oxidation inhibitors in the treatment of diabetes mellitus
69. Aryl substituted 2-oxirane carboxylic: A new group of antidiabetic compounds
70. The effects of etomoxir on insulin sensitivity in type 2 diabetic patients
71. Inhibition by etomoxir of CPT reduces hepatic glucose production and plasma lipids in NIDDM
72. Metabolic control and prevention of nephropathy by 2-totradceylglycidate in the diabetic mouse (db/db)
73. Direct evidence for the atypical nature of functional beta receptors in rat adipocytes
74. BRL 35135, a potent and selective beta adrenoceptor agonist
75. New pharmacological approaches to therapy of NIDDM
76. Adenosine receptors
77. Suppresion of non esterified fatty acid and triacylglycerol in experimental animals by the adenosine analogue GR 79236
78. Hypoglycemic action of antilipolytic agents
79. Use of aldose reductase inhibitors to chance insulin sensitivity in diabetes mellitus. PCT Int Appl WO 8806, 887(cl.AC1K3/50), 22 Sept. 1988, us appl. 28 512 20 mar 1987
80. Efficacy of 24-week monotherapy with acarbose glibenclamide, or placebo in NIDDM patients the essen study
81. New α-2 adrenergic blocker (DG-5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients
82. Effect on an α-2 adrenergic blocker (MK-912) on pancreatic islet function in non-insulin dependent diabetes mellitus
83. Pharmacology and molecular biology of islet cell adrenoceptors
84. Effects of α-2 adrenergic agonism, imidazolines and G-protein on insulin secretion in b-cells metabolism
85. Gene therapy for type 1 and type 2 diabetes